Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
Oncogene ; 35(43): 5619-5628, 2016 10 27.
Article in English | MEDLINE | ID: mdl-27157616

ABSTRACT

Gastric carcinoma is the third leading cause of cancer-related death worldwide. This cancer, most of the time metastatic, is essentially treated by surgery associated with conventional chemotherapy, and has a poor prognosis. The existence of cancer stem cells (CSC) expressing CD44 and a high aldehyde dehydrogenase (ALDH) activity has recently been demonstrated in gastric carcinoma and has opened new perspectives to develop targeted therapy. In this study, we evaluated the effects of all-trans-retinoic acid (ATRA) on CSCs in human gastric carcinoma. ATRA effects were evaluated on the proliferation and tumorigenic properties of gastric carcinoma cells from patient-derived tumors and cell lines in conventional 2D cultures, in 3D culture systems (tumorsphere assay) and in mouse xenograft models. ATRA inhibited both tumorspheres initiation and growth in vitro, which was associated with a cell-cycle arrest through the upregulation of cyclin-dependent kinase (CDK) inhibitors and the downregulation of cell-cycle progression activators. More importantly, ATRA downregulated the expression of the CSC markers CD44 and ALDH as well as stemness genes such as Klf4 and Sox2 and induced differentiation of tumorspheres. Finally, 2 weeks of daily ATRA treatment were sufficient to inhibit gastric tumor progression in vivo, which was associated with a decrease in CD44, ALDH1, Ki67 and PCNA expression in the remaining tumor cells. Administration of ATRA appears to be a potent strategy to efficiently inhibit tumor growth and more importantly to target gastric CSCs in both intestinal and diffuse types of gastric carcinoma.


Subject(s)
Antineoplastic Agents/pharmacology , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/metabolism , Stomach Neoplasms/metabolism , Stomach Neoplasms/pathology , Tretinoin/pharmacology , Aldehyde Dehydrogenase/metabolism , Animals , Biomarkers , Cell Cycle Checkpoints/drug effects , Cell Cycle Checkpoints/genetics , Cell Line, Tumor , Cell Proliferation/drug effects , Disease Models, Animal , Female , Humans , Hyaluronan Receptors/metabolism , Immunophenotyping , Kruppel-Like Factor 4 , Mice , Spheroids, Cellular , Stomach Neoplasms/drug therapy , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
2.
Cell Death Differ ; 23(3): 430-41, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26292757

ABSTRACT

Cell-cycle inhibitors of the Ink4 and Cip/Kip families are involved in cellular senescence and tumor suppression. These inhibitors are individually dispensable for the cell cycle and inactivation of specific family members results in increased proliferation and enhanced susceptibility to tumor development. We have now analyzed the consequences of eliminating a substantial part of the cell-cycle inhibitory activity in the cell by generating a mouse model, which combines the absence of both p21(Cip1) and p27(Kip1) proteins with the endogenous expression of a Cdk4 R24C mutant insensitive to Ink4 inhibitors. Pairwise combination of Cdk4 R24C, p21-null and p27-null alleles results in frequent hyperplasias and tumors, mainly in cells of endocrine origin such as pituitary cells and in mesenchymal tissues. Interestingly, complete abrogation of p21(Cip1) and p27(Kip1) in Cdk4 R24C mutant mice results in a different phenotype characterized by perinatal death accompanied by general hypoplasia in most tissues. This phenotype correlates with increased replicative stress in developing tissues such as the nervous system and subsequent apoptotic cell death. Partial inhibition of Cdk4/6 rescues replicative stress signaling as well as p53 induction in the absence of cell-cycle inhibitors. We conclude that one of the major physiological activities of cell-cycle inhibitors is to prevent replicative stress during development.


Subject(s)
Cyclin-Dependent Kinase Inhibitor Proteins/physiology , Cyclin-Dependent Kinase Inhibitor p21/physiology , Cyclin-Dependent Kinase Inhibitor p27/physiology , DNA Replication , Animals , Cell Self Renewal , Cyclin-Dependent Kinase 4/physiology , Genes, Lethal , Hemangiosarcoma/genetics , Mice , Mice, Knockout , Neural Stem Cells/physiology , Pituitary Neoplasms/genetics , Stress, Physiological
3.
Oncogene ; 34(20): 2547-55, 2015 May 14.
Article in English | MEDLINE | ID: mdl-25043305

ABSTRACT

Helicobacter pylori infection is now recognized as the main and specific infectious cause of cancer in the world. It is responsible for gastric adenocarcinomas of both intestinal and diffuse types, which are the long-term consequences of the chronic infection of the gastric mucosa. Case-control studies have shown an association between the two, recognized as early as 1994 and further substantiated by interventional studies in which H. pylori eradication has led to the prevention of at least part of the gastric cancers. Experimental studies have highlighted the role of bone marrow-derived cells (BMDCs) and particularly mesenchymal stem cells, in the neoplastic process in about a quarter of the cases and possibly an epithelial-mesenchymal transition (EMT) in the other cases. Different studies have confirmed that chronic infection with H. pylori induces a chronic inflammation and subsequent damage of the gastric epithelial mucosa, leading to BMDC recruitment. Once recruited, these cells home and differentiate by cell-cell fusion with local gastric epithelial cells, bearing local stem cell failure and participating in tissue regeneration. The context of chronic infection and inflammation leads to an EMT and altered tissue regeneration and differentiation from both local epithelial stem cells and BMDC. EMT induces the emergence of CD44+ cells possessing mesenchymal and stem cell properties, resulting in metaplastic and dysplastic lesions to give rise, after additional epigenetic and mutational events, to the emergence of cancer stem cells (CSCs) and adenocarcinoma.


Subject(s)
Adenocarcinoma/metabolism , Cell Transformation, Neoplastic/metabolism , Helicobacter Infections/metabolism , Helicobacter pylori/metabolism , Mesenchymal Stem Cells/metabolism , Neoplastic Stem Cells/metabolism , Stomach Neoplasms/metabolism , Adenocarcinoma/etiology , Adenocarcinoma/pathology , Animals , Cell Transformation, Neoplastic/pathology , Chronic Disease , Epithelial-Mesenchymal Transition , Helicobacter Infections/pathology , Humans , Inflammation , Mesenchymal Stem Cells/pathology , Neoplastic Stem Cells/pathology , Stomach Neoplasms/etiology , Stomach Neoplasms/pathology
4.
Article in English | MEDLINE | ID: mdl-23669204

ABSTRACT

Hypereosinophilic syndrome (HES) is a rare disease defined by organ damage directly attributable to hypereosinophilia of any type. Here, we report for the first time the case of a patient with a lymphocytic type of HES (HES-L) who had liver, skin, spleen, lung, bone marrow, digestive track, and mouth involvement. Associated T-cells displayed an aberrant CD30+ phenotype and were monoclonal. Thymus activated and regulated chemokine serum level was positive. Despite steroids (Cortancyl 20 mg [Sanofi Aventis, France], imatinib mesylate [Glivec 400 mg; Novartis Europharm], interferon alpha 2A [Roferon-A 3 MUI/0.5 ml; Roche]) and other lines of therapy including imatinib mesylate treatment, an oral necrotic lesion developed, and finally progressed into a peripheral CD30+ T-cell lymphoma. CHOP chemotherapy (cyclophosphamide, hydroxydoxorubicin, oncovin, prednisone), interferon-α, and mepolizumab were ineffective. Although progression into peripheral T-cell lymphoma is documented as a rare complication of HES-L, severe oral extension of HES-L is described for the first time.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Hypereosinophilic Syndrome/complications , Lymphoma, T-Cell, Peripheral/etiology , Mouth Mucosa/pathology , Aged , Fatal Outcome , Humans , Hypereosinophilic Syndrome/pathology , Lymphoma, T-Cell, Peripheral/pathology , Male , Tomography, X-Ray Computed
5.
Diabetologia ; 52(8): 1608-17, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19513688

ABSTRACT

AIMS/HYPOTHESIS: Wingless and iNT-1 (WNT) pathway members are critical for pancreatic development and exocrine tissue formation. Recently, much attention has focused on delineating the roles of beta-catenin in pancreatic organogenesis. However, little is known about the involvement of beta-catenin in the endocrine or exocrine function of the mature pancreas. We report for the first time the impact of beta-catenin deletion in the pancreatic beta cells. METHODS: We targeted the deletion of the beta-catenin gene in pancreatic beta cells by crossing a floxed beta-catenin mouse strain with a RIP-Cre mouse strain. RESULTS: Surprisingly, the majority of the mutant mice died shortly after birth and had deregulated glucose and insulin levels. The newborn mutant pancreases demonstrated increased insulin content, reflecting a defect in insulin release confirmed in vitro. Moreover, there was a reduction in total endocrine tissue at birth, while cellularity in islets was greater, suggesting that lack of beta-catenin affects beta cell size. Some newborns survived beta-catenin deletion and showed a milder phenotype during adulthood. CONCLUSIONS/INTERPRETATION: The deletion of beta-catenin in the maturing beta cells negatively impacts on islet morphology and function. This work reveals that lack of beta-catenin in early life is related to severe deregulation of glucose homeostasis.


Subject(s)
Blood Glucose/metabolism , Islets of Langerhans/pathology , beta Catenin/deficiency , Animals , Animals, Newborn , Crosses, Genetic , DNA/genetics , DNA/isolation & purification , Gene Deletion , Hyperglycemia/genetics , Hyperinsulinism/genetics , Hypoglycemia/genetics , Insulin/metabolism , Insulin Secretion , Mice , Mice, Inbred Strains , Polymerase Chain Reaction , beta Catenin/genetics
6.
J Pathol ; 217(1): 4-13, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19016567

ABSTRACT

The generation of new mouse models of human disease is accelerating rapidly, due to the completion of whole-genome sequencing efforts and technological advances in the manipulation of the mouse genome. We sought to investigate manpower issues in the provision of histopathology expertise for mouse functional genomics and compared this to the perceived demand from principal investigators (PIs). Through the European Commission (EC)-funded PRIME pathology training initiative, two questionnaires were devised to collect information from pathologists and EC-funded PIs on the current provision of mouse histopathology expertise in Europe and the demands for this service. We find that pathological analysis is being performed almost exclusively by professionally qualified pathologists, generally employed in clinical diagnostic posts, where the work is undertaken as collaboration outside of their contractual commitments but without previous training in veterinary or comparative pathology. The results indicate that there is a lack of both trainees and provision of specialist training in this field. Unsurprisingly, the availability of diagnostic expertise and advice falls far short of the number of genetically engineered mice (GEM) being generated for analysis. We analyse these results with reference to previous studies and discuss solutions for the future recruitment, training and funding for pathologists in mouse functional genomics in Europe.


Subject(s)
Disease Models, Animal , Genomics , Pathology, Veterinary , Animals , Clinical Competence , Europe , Genomics/standards , Genomics/statistics & numerical data , Mice , Pathology, Veterinary/standards , Pathology, Veterinary/statistics & numerical data , Personnel Selection/statistics & numerical data , Surveys and Questionnaires , Workforce , Workload/statistics & numerical data
7.
Int J Radiat Biol ; 84(11): 930-6, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19016141

ABSTRACT

PURPOSE: The European Radiobiology Archives (ERA), together with corresponding Japanese and American databases, hold data from nearly all experimental animal radiation biology studies carried out between 1960 and 1998, involving more than 300,000 animals. The Federal Office for Radiation Protection, together with the University of Cambridge have undertaken to transfer the existing ERA archive to a web-based database to maximize its usefulness to the scientific community and bring data coding and structure of this legacy database into congruence with currently accepted semantic standards for anatomy and pathology. METHODS: The accuracy of the primary data input was assessed and improved. The original rodent pathology nomenclature was recoded to replace the local 'DIS-ROD' (Disease Rodent) formalism with Mouse Pathology (MPATH) and Mouse Anatomy (MA) ontology terms. A pathology panel sampled histopathological slide material and compared the original diagnoses with currently accepted diagnostic criteria. RESULTS: The overall non-systematic error rate varied among the studies between 0.26% and 4.41%, the mean error being 1.71%. The errors found have been corrected and the studies thus controlled have been annotated. The majority of the original pathology terms have been successfully translated into a combination of MPATH and MA ontology terms. CONCLUSIONS: ERA has the potential of becoming a world-wide radiobiological research tool for numerous applications, such as the re-analysis of existing data with new approaches in the light of new hypotheses and techniques, and using the database as an information resource for planning future animal studies. When the database is opened for new data it may be possible to offer long-term storage of data from recent and future animal studies.


Subject(s)
Databases, Factual/trends , Radiobiology , Animals , Archives , Europe , Humans , Internet , Radiology Information Systems , Terminology as Topic , User-Computer Interface
8.
Oncogene ; 26(55): 7665-74, 2007 Dec 06.
Article in English | MEDLINE | ID: mdl-17599058

ABSTRACT

Cell-cycle inhibitors of the Cip/Kip and INK4 families are involved in cellular senescence and tumor suppression. Some of these proteins, p21(Cip1), p16(INK4a) and p15(INK4b), are coexpressed in response to antiproliferative signals such as cellular senescence resulting in cell-cycle arrest. To understand the roles of these inhibitors and their synergistic effect, we have characterized the growth properties and senescent behavior of primary cells deficient in p21(Cip1) and expressing an endogenous Cdk4(R24C) (cyclin-dependent kinase) mutant (Cdk4(R24C) knock-in cells) insensitive to INK4 proteins. Inactivation of both p21(Cip1) and INK4 pathways strongly cooperate in suppressing cellular senescence in vitro. These double mutant cells behavior as immortal cultures and display high sensitivity to cellular transformation by oncogenes. Moreover, mice double mutant in the INK4 and p21(Cip1) pathways (Cdk4(R24C); p21(Cip1)-null mice) display an increased incidence of specific sarcomas, suggesting a significant cooperation between these two families of cell-cycle inhibitors in senescence responses and tumor suppression in vivo.


Subject(s)
Cellular Senescence/genetics , Cyclin-Dependent Kinase Inhibitor Proteins/physiology , Sarcoma/genetics , Animals , Cyclin-Dependent Kinase 4/genetics , Cyclin-Dependent Kinase Inhibitor Proteins/genetics , Cyclin-Dependent Kinase Inhibitor p15/genetics , Cyclin-Dependent Kinase Inhibitor p15/physiology , Cyclin-Dependent Kinase Inhibitor p16/genetics , Cyclin-Dependent Kinase Inhibitor p16/physiology , Cyclin-Dependent Kinase Inhibitor p21/genetics , Cyclin-Dependent Kinase Inhibitor p21/physiology , Mice , Mice, Mutant Strains , Sarcoma/metabolism , Sarcoma/pathology
9.
J Clin Pathol ; 59(10): 1111-3, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17021140

ABSTRACT

Clonality analysis of the immunoglobulin heavy chain (IgH) gene is helpful in identifying malignant B cell infiltrates in the bone marrow and is usually carried out on separate aspirates or on the same formalin-fixed decalcified bone marrow specimen. To determine whether the removal of the decalcification step would improve the molecular analysis, we first studied 12 bone marrow specimens with lymphoma infiltration split into a fixed and a small frozen fragment. Both the detection rate of IgH gene monoclonality and DNA quality were found to be superior in the frozen part than in the fixed part. Conversely, to evaluate whether the split would compromise histological analysis, we selected a series of 134 bone marrow specimens obtained from patients with small B cell lymphoma and showing IgH monoclonality on the frozen part. The histological detection rate of infiltrated or suspicious infiltrates (95%) on the fixed part was not altered by saving a frozen part.


Subject(s)
Bone Marrow/pathology , Lymphoma, B-Cell/pathology , Biopsy , Bone Marrow Examination/methods , Cryopreservation , DNA, Neoplasm/analysis , Humans , Immunoglobulin Heavy Chains/genetics , Lymphoma, Follicular/pathology , Neoplasm Invasiveness , Neoplasm Staging/methods , Tissue Fixation/methods
10.
Histopathology ; 48(4): 353-62, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16487357

ABSTRACT

AIMS: The recognition of blastoid variant (BV) of mantle cell lymphoma (MCL) is based on morphological criteria. Our aim was to analyse 18 MCL cases including four BV-MCL for their clinicopathological features, proliferation index, cyclin D1 and CDK4 expression and interphase fluorescence in-situ hybridization (FISH) pattern. METHODS AND RESULTS: BV-MCL versus common MCL was characterized by a shorter overall duration of response after first-line therapy (11 months versus 28 months) and shorter overall survival (20 months versus 42 months). Interphase FISH showed a t(11;14) fusion pattern in all MCL tested cases. However, the four blastoid cases were characterized by extra copies of CCND1 signals. Using additional probes of chromosomes 11, 18, 21, these signals were shown to be the result of hypotetraploidy and not of a specific amplification of the normal or the translocated CCND1 allele. Moreover, the BV-MCL cases were characterized by a combined high percentage of cells expressing cyclin D1 and/or CDK4 with a proliferation (MIB-1-Ki67) index above 50%. Such features allowed the recognition of areas of large cell transformation in the case of secondary BV-MCL. CONCLUSIONS: Since distinction between BV and common MCL is of clinical relevance, our data underline the need to add phenotypic and cytogenetic criteria to cytomorphology for a better recognition of BV-MCL.


Subject(s)
Lymphocytes/pathology , Lymphoma, Mantle-Cell/pathology , Neoplastic Stem Cells/pathology , Adult , Aged , Antigens, CD20/analysis , CD5 Antigens/analysis , Chromosomes, Human, Pair 11/genetics , Chromosomes, Human, Pair 14/genetics , Cyclin D1/analysis , Cyclin D1/genetics , Cyclin-Dependent Kinase 4/analysis , Female , Humans , Immunohistochemistry , In Situ Hybridization, Fluorescence , Interphase/genetics , Ki-67 Antigen/analysis , Leukosialin/analysis , Lymphoma, Mantle-Cell/genetics , Lymphoma, Mantle-Cell/metabolism , Male , Middle Aged , Reverse Transcriptase Polymerase Chain Reaction , Survival Analysis , Translocation, Genetic , Treatment Outcome
11.
Genomics ; 87(1): 84-92, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16314073

ABSTRACT

Congenital erythropoietic porphyria (CEP) is a recessive autosomal disorder characterized by a deficiency in uroporphyrinogen III synthase (UROS), the fourth enzyme of the heme biosynthetic pathway. The severity of the disease, the lack of specific treatment except for allogeneic bone marrow transplantation, and the knowledge of the molecular lesions are strong arguments for gene therapy. An animal model of CEP has been designed to evaluate the feasibility of retroviral gene transfer in hematopoietic stem cells. We have previously demonstrated that the knockout of the Uros gene is lethal in mice (Uros(del) model). This work describes the achievement of a knock-in model, which reproduces a mutation of the UROS gene responsible for a severe UROS deficiency in humans (P248Q missense mutant). Homozygous mice display erythrodontia, moderate photosensitivity, hepatosplenomegaly, and hemolytic anemia. Uroporphyrin (99% type I isomer) accumulates in urine. Total porphyrins are increased in erythrocytes and feces, while Uros enzymatic activity is below 1% of the normal level in the different tissues analyzed. These pathological findings closely mimic the CEP disease in humans and demonstrate that the Uros(mut248) mouse represents a suitable model of the human disease for pathophysiological, pharmaceutical, and therapeutic purposes.


Subject(s)
Amino Acid Substitution , Mutation, Missense , Porphyria, Erythropoietic/enzymology , Uroporphyrinogen III Synthetase/genetics , Animals , Bone Marrow Transplantation , Disease Models, Animal , Genetic Therapy , Mice , Mice, Transgenic , Porphyria, Erythropoietic/pathology , Porphyria, Erythropoietic/therapy , Uroporphyrinogen III Synthetase/metabolism , Uroporphyrins/metabolism
13.
Article in English | MEDLINE | ID: mdl-16869759

ABSTRACT

Most human tumors harbor mutations that misregulate the early phases of the cell cycle. Here, we summarize genetic evidence, mostly obtained in our laboratory using strains of gene-targeted mice, that provides direct experimental support for a role of Cdk4 in tumor development. Moreover, these genetic studies challenge some well-established concepts regarding the role of Cdks during the early phases of the cell cycle. For instance, they have illustrated that Cdk4 and Cdk6 are not essential for cell division during embryonic development except in the hematopoietic system. More surprisingly, mice lacking Cdk2 survive for over 2 years without detectable abnormalities except in their germ cells, indicating that Cdk2 is essential for meiosis but dispensable for the normal mitotic cell cycle. Cdk2 is also dispensable for cell cycle inhibition and tumor suppression by the Cip/Kip inhibitors, p21(Cip1) and p27(Kip1). These observations have important implications not only to understand cell cycle regulation, but also to validate Cdks as potential targets for the development of therapeutic strategies to block proliferation of tumor cells.


Subject(s)
Cell Cycle/genetics , Cell Cycle/physiology , Cyclin-Dependent Kinases/genetics , Mutation , Neoplasms/enzymology , Neoplasms/genetics , Animals , Cyclin-Dependent Kinase 2/deficiency , Cyclin-Dependent Kinase 2/genetics , Cyclin-Dependent Kinase 2/physiology , Cyclin-Dependent Kinase 4/deficiency , Cyclin-Dependent Kinase 4/genetics , Cyclin-Dependent Kinase 4/physiology , Cyclin-Dependent Kinase 6/deficiency , Cyclin-Dependent Kinase 6/genetics , Cyclin-Dependent Kinase 6/physiology , Cyclin-Dependent Kinase Inhibitor p21/physiology , Cyclin-Dependent Kinase Inhibitor p27/physiology , Cyclin-Dependent Kinases/deficiency , Cyclin-Dependent Kinases/physiology , Female , Fetal Death/genetics , Genes, Lethal , Humans , Meiosis , Melanoma, Experimental/enzymology , Melanoma, Experimental/genetics , Melanoma, Experimental/pathology , Mice , Mice, Knockout , Mitosis , Neoplasms/pathology , Pregnancy
14.
Clin Neuropathol ; 22(1): 10-3, 2003.
Article in English | MEDLINE | ID: mdl-12617188

ABSTRACT

Metastasis from an extracranial tumor to a primary central nervous system tumor is a rare event, and most reported cases concern metastases to meningiomas. The authors describe the first case of leukemic cell dissemination within a glioblastoma. The patient likely presented a genetic predisposition to multiple neoplasms, and the unusual localization of leukemic cells might be partly related to the characteristic microvascular proliferation in glioblastoma.


Subject(s)
Brain Neoplasms/pathology , Brain/pathology , Glioblastoma/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Leukemic Infiltration/pathology , Brain/diagnostic imaging , Brain Neoplasms/diagnostic imaging , Fatal Outcome , Glioblastoma/diagnostic imaging , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/diagnostic imaging , Leukemic Infiltration/diagnostic imaging , Male , Middle Aged , Tomography, X-Ray Computed
15.
J Pathol ; 198(2): 171-80, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12237876

ABSTRACT

By prospectively studying immunoglobulin heavy chain gene (IgH) and T cell receptor gamma (TCRgamma) gene rearrangements in 398 lymphoma cases, a dual genotype was observed in 13% of B cell and 11% of T cell lymphomas. According to histological subtype, the highest incidence was observed for mantle cell lymphomas (32%) and lymphoplasmacytic lymphoma (21%) among B cell lymphomas, and for angioimmunoblastic lymphoma (AILT) (46%) and Sézary syndrome (SS) (50%) among T cell lymphomas. To determine whether the dual genotype corresponds to the presence of two distinct monoclonal populations or to the presence of both rearrangements within the same lymphoma cells, single-cell microdissection was used after immunohistochemistry and a single-cell combined IgH and TCRgamma gene analysis was designed after a whole-genome amplification step. This protocol was applied to the study of two nodal B cell lymphomas (one diffuse large B cell lymphoma and one mantle cell lymphoma) and two cutaneous T cell lymphomas (one AILT and one SS). Two cases (SS and mantle cell lymphoma) were true bigenotypic lymphomas, as both IgH and TCRgamma monoclonal rearrangements were detected in the same cells. Conversely, in the diffuse large B cell lymphoma and AILT cases, large CD22+ single cells exhibited only the monoclonal IgH rearrangement but not the TCRgamma gene that was detected in CD3+ single cells. Such an approach allows the identification of true bigenotypic lymphoma among dual genotypic lymphoma. Specific genetic alterations may be further amplified from microdissected cryopreserved material, such as the t(11;14) breakpoint detected in bigenotypic B cells of the mantle cell lymphoma case.


Subject(s)
Gene Rearrangement, B-Lymphocyte, Heavy Chain , Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor , Lymphoma, B-Cell/genetics , Lymphoma, T-Cell/genetics , Chromosomes, Human, Pair 11 , Chromosomes, Human, Pair 14 , Cryopreservation , Genotype , Humans , Lymphoma, B-Cell/pathology , Lymphoma, T-Cell/pathology , Polymerase Chain Reaction/methods , Prospective Studies , Translocation, Genetic
16.
EMBO J ; 20(23): 6637-47, 2001 Dec 03.
Article in English | MEDLINE | ID: mdl-11726500

ABSTRACT

We have introduced a point mutation in the first coding exon of the locus encoding the cyclin-dependent kinase 4 (Cdk4) by homologous recombination in embryonic stem cells. This mutation (replacement of Arg24 by Cys) was first found in patients with hereditary melanoma and renders Cdk4 insensitive to INK4 inhibitors. Here, we report that primary embryonic fibroblasts expressing the mutant Cdk4R24C kinase are immortal and susceptible to transformation by Ras oncogenes. Moreover, homozygous Cdk4(R24C/R24C) mutant mice develop multiple tumors with almost complete penetrance. The most common neoplasia (endocrine tumors and hemangiosarcomas) are similar to those found in pRb(+/-) and p53(-/-) mice. This Cdk4 mutation cooperates with p53 and p27(Kip1) deficiencies in decreasing tumor latency and favoring development of specific tumor types. These results provide experimental evidence for a central role of Cdk4 regulation in cancer and provide a valuable model for testing the potential anti-tumor effect of Cdk4 inhibitors in vivo.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p16/antagonists & inhibitors , Cyclin-Dependent Kinases/genetics , Cyclin-Dependent Kinases/physiology , Mice, Knockout , Proto-Oncogene Proteins , 3T3 Cells , Alleles , Animals , Blotting, Western , Cell Cycle , Cell Cycle Proteins/genetics , Cyclin-Dependent Kinase 4 , Cyclin-Dependent Kinase Inhibitor p27 , Exons , Female , Fibroblasts/metabolism , Gene Expression Regulation, Neoplastic , Genes, p53/genetics , Genes, ras/genetics , Genetic Predisposition to Disease , Homozygote , Humans , Lymphoma/genetics , Male , Melanoma/genetics , Melanoma/metabolism , Mice , Molecular Sequence Data , Mutation , Point Mutation , Precipitin Tests , Protein Biosynthesis , Recombination, Genetic , Sarcoma/genetics , Sex Factors , Teratoma/genetics , Time Factors , Transformation, Genetic , Tumor Suppressor Protein p14ARF/genetics , Tumor Suppressor Proteins/genetics
17.
Morphologie ; 85(270): 15-22, 2001 Sep.
Article in French | MEDLINE | ID: mdl-11723817

ABSTRACT

Cytogenetic analyses have revealed that mantle cell lymphomas (MCL) are closely associated with the t(11;14)(q13;q32). This translocation juxtaposes the immunoglobulin heavy chain gene (IGH) sequences with the BCL-1 locus, leading to up-regulation of the CCND1 gene and consequently to an overexpression of cyclin D1 protein. We studied 27 MCL with characteristic morphological and immunological (CD5+, CD10-, CD20+, CD23-) features and 2 controls (reactionnal lymphadenitis) to evaluate the feasibility and the interest of FISH analysis on interphase cells from frozen or paraffin-embedded tissues. Sections (CC) and touch preparations (EC) of frozen tissues and sections of paraffin-embedded tissues (CF) were successfully hybridized with the Vysis LSI IgH/CCND1 dual color dual fusion translocation probe. The touch preparations presented a lower cellularity than sections, therefore allowing an easier analysis. Hybridization spots intensities were found stronger in CC and EC than in CF. The percentages of t(11;14) positive cells were similar in CC, EC and CF from a same patient. The percentage of non hybridized cells, analogous in CC and EC, was higher in CF. However, the CF were directly analysed on microscope without the need of any numerical picture treatment. The t(11;14) was detected in all the cases (27/27) and positive cells percentages were always higher than the probe cut-off (5%). The FISH analysis on interphase cells appears a performing and rapid technique to detect t(11;14) in MCL on both frozen and paraffin-embedded tissue, thus extending its practical and diagnostic use.


Subject(s)
Cyclin D1/analysis , Cyclin D1/genetics , Lymphoma, Mantle-Cell/chemistry , Lymphoma, Mantle-Cell/genetics , Freezing , Humans , In Situ Hybridization, Fluorescence , Paraffin Embedding , Translocation, Genetic
18.
Proc Natl Acad Sci U S A ; 98(23): 13312-7, 2001 Nov 06.
Article in English | MEDLINE | ID: mdl-11606789

ABSTRACT

Many human tumors harbor mutations that result in deregulation of Cdk4 activity. Most of these mutations involve overexpression of D-type cyclins and inactivation of INK4 inhibitors. In addition, a mutation in the Cdk4 protein has been described in patients with familial melanoma (Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., et al. (1995) Science 269, 1281-1284; Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., et al. (1996) Nat. Genet. 12, 97-99). This mutation, R24C, renders the Cdk4 protein insensitive to inhibition by INK4 proteins including p16(INK4a), a major candidate for the melanoma susceptibility locus. Here we show that knock-in mice expressing a Cdk4 R24C allele are highly susceptible to melanoma development after specific carcinogenic treatments. These tumors do not have mutations in the p19(ARF)/p53 pathway, suggesting a specific involvement of the p16(INK4a)/Cdk4/Rb pathway in melanoma development. Moreover, by using targeted mice deficient for other INK4 inhibitors, we show that deletion of p18(INK4c) but not of p15(INK4b) confers proliferative advantage to melanocytic tumor growth. These results provide an experimental scenario to study the role of Cdk4 regulation in melanoma and to develop novel therapeutic approaches to control melanoma progression.


Subject(s)
Cyclin-Dependent Kinases/physiology , Melanoma, Experimental/genetics , Proto-Oncogene Proteins , Animals , Cyclin-Dependent Kinase 4 , Cyclin-Dependent Kinase Inhibitor p16/antagonists & inhibitors , Cyclin-Dependent Kinase Inhibitor p16/genetics , Cyclin-Dependent Kinases/genetics , Genes, Tumor Suppressor , Genetic Predisposition to Disease , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Neoplasm Invasiveness
19.
J Invest Dermatol ; 117(4): 920-6, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11676833

ABSTRACT

The monoclonality of the T cell receptor gamma-chain gene was analyzed by polymerase chain reaction in skin and blood specimens of 85 patients with cutaneous T cell lymphomas including 67 mycosis fungoides, seven Sézary syndromes, and 11 CD30- nonepidermotropic cutaneous T cell lymphomas. A cutaneous T cell clone was detected in 69% of mycosis fungoides and 100% of Sézary syndromes. This frequency varied according to the clinical stage: 57% in early stages (Ia-IIa) to 96% in advanced stages (IIb-IV, Sézary syndrome). A peripheral blood T cell clone was detected in 42% of early stages and in 74% of late stages but was identical to the cutaneous one in 15% and in 63%, respectively. A significant association between initial clinical stage and T cell monoclonality was observed. In nonepidermotropic cutaneous T cell lymphomas, T cell monoclonality was detected in 55% of skin and 36% of blood samples. Univariate and multivariate analyses showed that, besides the initial clinical stage, an identical cutaneous and blood T cell clone was an independent prognostic factor for disease progression of mycosis fungoides/Sézary syndrome (hazard ratio 3.4, 95% confidence interval 1.4-9.9). Parallel polymerase chain reaction study of skin and blood specimens may therefore provide an initial prognostic marker that could help to monitor therapeutic strategies. A fully prospective study, with simultaneous therapeutic trials, needs to be done to confirm our findings and to include treatment variables in the statistical analysis.


Subject(s)
Blood Cells/pathology , Lymphoma, T-Cell/pathology , Skin Neoplasms/pathology , Skin/pathology , T-Lymphocytes/pathology , Adult , Aged , Aged, 80 and over , Clone Cells , Female , Humans , Male , Middle Aged , Neoplasm Staging , Polymerase Chain Reaction , Prognosis
20.
Br J Haematol ; 113(4): 1047-50, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11442501

ABSTRACT

True histiocytic lymphoma (THL) is a very rare type of non-Hodgkin's lymphoma (NHL) in which neoplastic cells exhibit markers of histiocytic differentiation. Some cases of THL have been reported in patients with previous acute lymphoblastic leukaemia (ALL), especially in children and young adults, in whom the acute leukaemia was of T-cell origin. The relationship between the initial lymphoid tumour and the secondary THL remains unclear, as a common monoclonal origin shared by both neoplasms has never been definitively demonstrated. We report a patient with B-ALL who developed a nodal and extranodal tumour with histological and immunohistochemical features of THL 4 years after the initial diagnosis. Genotypic study showed that both neoplasms contained the same immunoglobulin heavy gene rearrangement, which has not been reported previously.


Subject(s)
Burkitt Lymphoma/complications , Burkitt Lymphoma/genetics , Gene Rearrangement, B-Lymphocyte, Heavy Chain , Lymphoma, Large B-Cell, Diffuse/complications , Lymphoma, Large B-Cell, Diffuse/genetics , Adult , Antigens, CD/analysis , Antigens, Differentiation, Myelomonocytic/analysis , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Burkitt Lymphoma/diagnosis , Cyclophosphamide/administration & dosage , Dacarbazine/administration & dosage , Daunorubicin/administration & dosage , Humans , Immunohistochemistry , Leukocyte Common Antigens/analysis , Lymphoma, Large B-Cell, Diffuse/diagnosis , Male , Polymerase Chain Reaction , S100 Proteins/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...